Ulysses Neuroscience is a contract research organization that provides preclinical and clinical research services to pharmaceutical companies focused on psychiatric diseases and rare neurological disorders. Its core offerings include clinical biomarker services, biomarker and cell-culture operations, and development of assays such as an electroencephalographic (EEG) assay for psychedelic and depression research alongside gene-therapy work for rare neurodevelopmental diseases. The company reports annual revenue of over €1m and had net assets of €342,300 at the end of 2021. Ulysses recently relocated to the newly built Pioneer Group life sciences facilities in Cherrywood to scale its laboratory capabilities and is hiring for preclinical and clinical neuroscience roles. It also maintains a presence at Trinity College Dublin where its preclinical scientists are developing assays and gene-therapy approaches. With the new capital, Ulysses plans to expand its market reach to the US, EU and Asia and to grow its clinical biomarker services.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2024